Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 18;24(8):1534.
doi: 10.3390/molecules24081534.

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution

Affiliations

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution

Anton Larenkov et al. Molecules. .

Abstract

Zirconium-89 is a promising radionuclide for nuclear medicine. The aim of the present work was to find a suitable method for obtaining zirconium-89 solutions for radiopharmaceutical purposes. For this purpose, the ion exchange behavior of zirconium-89 solutions was studied. Radio-TLC (thin layer chromatography) and biodistribution studies were carried out to understand speciation of zirconium-89 complexes and their role in the development of new radiopharmaceuticals. Three methods of zirconium-89 isolation were studied using ZR (hydroxamate) and Chelex-100 resins. It was found that ZR-resin alone is not enough to obtain stable zirconium-89 formulations. An easy and effective method of reconstitution of [89Zr]Zr-oxalate to [89Zr]Zr-citrate using Chelex-100 resin was developed. Developed procedures allow obtaining [89Zr]Zr-oxalate (in 0.1 M sodium oxalate solution) and [89Zr]Zr-citrate (in 0.1-1.0 M sodium citrate solution). These solutions are perfectly suitable and convenient for radiopharmaceutical purposes. Our results prove [89Zr]Zr-citrate to be advantageous over [89Zr]Zr-oxalate. During evaluation of speciation of zirconium-89 complexes, a new TLC method was developed, since it was proved that there is no comprehensive method for analysis or zirconium-89 preparations. The new method provides valuable insights about the content of "active" ionic form of zirconium-89. The interrelation of the chromatographic behavior of zirconium-89 preparations and their biodistribution was studied.

Keywords: Chelex-100; DFO; ZR hydroxamate resin; citrate; oxalate; purification; radiochemical purity; stability; transchelation; zirconium-89.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
Dependence of zirconium-89 distribution coefficients (Dg) on oxalic acid concentration for Chelex-100 resin.
Figure 2
Figure 2
Dependence of zirconium-89 elution efficiency using different sodium carboxylates solutions as eluents with Chelex-100 resin (load from 0.5 M oxalic acid medium: losses at the sorption step—0.7%; losses at the washing step (0.1 M oxalic acid)—0.3%).
Figure 3
Figure 3
Dependence of zirconium-89 elution efficiency from Chelex-100 on sodium citrate concentration in eluent.
Figure 4
Figure 4
The dependence of [89Zr]Zr-DFO complex formation yield on the amount of chelator for various formulations of zirconium-89.
Figure 5
Figure 5
μPET maximum intensity projections of mice after 24 h p.i. of [89Zr]Zr-oxalate samples listed at Table 5: (a) Sample 1; (b) Sample 2; (c) Sample 3; and (d) Sample 4.

Similar articles

Cited by

References

    1. Knapp F.F., Dash A. Radiopharmaceuticals for Therapy. Springer; New Delhi, India: 2016. Introduction: Radiopharmaceuticals Play an Important Role in Both Diagnostic and Therapeutic Nuclear Medicine; pp. 3–23.
    1. Qin Z. Recent advances of injectable radiopharmaceuticals for nuclear imaging and therapy: A new era in nuclear medicine. Mater. Technol. 2015;30:B250–B255. doi: 10.1080/10667857.2015.1104829. - DOI
    1. Basu S., Alavi A. PET-Based Molecular Imaging in Evolving Personalized Management Design. PET Clin. 2016;11:203–362. doi: 10.1016/j.cpet.2016.03.002. - DOI - PubMed
    1. Vasdev N., Alavi A. Novel PET Radiotracers with Potential Clinical Applications. PET Clin. 2017;12:269–337. doi: 10.1016/j.cpet.2017.04.002. - DOI - PubMed
    1. Velikyan I. Prospective of 68Ga-Radiopharmaceutical Development. Theranostics. 2014;4:47–80. doi: 10.7150/thno.7447. - DOI - PMC - PubMed

LinkOut - more resources